These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35841068)

  • 21. Verification of placental growth factor and soluble-fms-like tyrosine kinase 1 assay performance in late pregnancy and their diagnostic test accuracy in women with reduced fetal movement.
    Armstrong-Buisseret LK; Haslam S; James T; Bradshaw L; Heazell AE
    Ann Clin Biochem; 2020 May; 57(3):223-233. PubMed ID: 32081030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maternal preconception and pregnancy tobacco and cannabis use in relation to placental developmental markers: A population-based study.
    Cajachagua-Torres KN; El Marroun H; Reiss IKM; Jaddoe VWV
    Reprod Toxicol; 2022 Jun; 110():70-77. PubMed ID: 35378220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.
    Ren Z; Cui N; Zhu M; Khalil RA
    Am J Physiol Heart Circ Physiol; 2018 Jul; 315(1):H33-H47. PubMed ID: 29569955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of adverse perinatal outcome by serum placental growth factor and soluble fms-like tyrosine kinase-1 in women undergoing induction of labor.
    Fiolna M; Machuca M; Karampitsakos T; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Nov; 54(5):604-608. PubMed ID: 31444934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome.
    Stepan H; Hund M; Andraczek T
    Hypertension; 2020 Apr; 75(4):918-926. PubMed ID: 32063058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Household air pollution and angiogenic factors in pregnant Nigerian women: A randomized controlled ethanol cookstove intervention.
    Dutta A; Brito K; Khramstova G; Mueller A; Chinthala S; Alexander D; Adu D; Ibigbami T; Olamijulo J; Odetunde A; Adigun K; Pruitt L; Olopade O; Ojengbede O; Rana S; Olopade CO
    Sci Total Environ; 2017 Dec; 599-600():2175-2181. PubMed ID: 28575932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio.
    Zhang F; Gu M; Chen P; Wan S; Zhou Q; Lu Y; Li L
    Placenta; 2022 Jun; 124():48-54. PubMed ID: 35635854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum placental growth factor and soluble fms-like tyrosine kinase 1 at mid-gestation in healthy women: Association with small-for-gestational-age neonates.
    Furuta I; Umazume T; Kojima T; Chiba K; Nakagawa K; Hosokawa A; Ishikawa S; Yamada T; Morikawa M; Minakami H
    J Obstet Gynaecol Res; 2017 Jul; 43(7):1152-1158. PubMed ID: 28422347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating angiogenic factors and placental abruption.
    Signore C; Mills JL; Qian C; Yu K; Lam C; Epstein FH; Karumanchi SA; Levine RJ
    Obstet Gynecol; 2006 Aug; 108(2):338-44. PubMed ID: 16880304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
    Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
    PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of adverse perinatal outcome and the mean time until delivery in twin pregnancies with suspected pre-eclampsia using sFlt-1/PIGF ratio.
    Karge A; Seiler A; Flechsenhar S; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B; Graupner O
    Pregnancy Hypertens; 2021 Jun; 24():37-43. PubMed ID: 33647841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maternal soluble fms-like tyrosine kinase-1, placental growth factor, plasminogen activator inhibitor-2, and folate concentrations and early fetal size: the Generation R study.
    Bouwland-Both MI; Steegers EA; Lindemans J; Russcher H; Hofman A; Geurts-Moespot AJ; Sweep FC; Jaddoe VW; Steegers-Theunissen RP
    Am J Obstet Gynecol; 2013 Aug; 209(2):121.e1-11. PubMed ID: 23583216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of circulating total sFLT-1 to placental-specific sFLT-1 e15a in women with suspected preeclampsia.
    Rowson S; Reddy M; De Guingand DL; Langston-Cox A; Marshall SA; da Silva Costa F; Palmer KR
    Placenta; 2022 Mar; 120():73-78. PubMed ID: 35227983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The sFlt-1/PlGF ratio as a predictor for poor pregnancy and neonatal outcomes.
    Chang YS; Chen CN; Jeng SF; Su YN; Chen CY; Chou HC; Tsao PN; Hsieh WS
    Pediatr Neonatol; 2017 Dec; 58(6):529-533. PubMed ID: 28571908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. sFlt-1/PlGF ratio and timing of delivery in early-onset fetal growth restriction with antegrade umbilical artery flow.
    Quezada MS; Rodríguez-Calvo J; Villalaín C; Gómez-Arriaga PI; Galindo A; Herraiz I
    Ultrasound Obstet Gynecol; 2020 Oct; 56(4):549-556. PubMed ID: 31840879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.
    Vatten LJ; Åsvold BO; Eskild A
    Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.